TWD 59.6
(5.86%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.3 Billion TWD | -26.42% |
2022 | 1.77 Billion TWD | 9.25% |
2021 | 1.62 Billion TWD | 21.44% |
2020 | 1.34 Billion TWD | -4.55% |
2019 | 1.4 Billion TWD | -4.13% |
2018 | 1.46 Billion TWD | 6.74% |
2017 | 1.37 Billion TWD | -2.64% |
2016 | 1.41 Billion TWD | -7.81% |
2015 | 1.52 Billion TWD | 22.14% |
2014 | 1.25 Billion TWD | -14.14% |
2013 | 1.45 Billion TWD | 9.33% |
2012 | 1.33 Billion TWD | 3.54% |
2011 | 1.28 Billion TWD | 13.3% |
2010 | 1.13 Billion TWD | 7.07% |
2009 | 1.06 Billion TWD | 15.71% |
2008 | 918.19 Million TWD | 61.0% |
2007 | 570.29 Million TWD | -1.3% |
2006 | 577.81 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 234.44 Million TWD | 125.13% |
2024 Q2 | 280.52 Million TWD | 19.65% |
2023 Q4 | 104.13 Million TWD | -67.75% |
2023 FY | 1.3 Billion TWD | -26.42% |
2023 Q1 | 313.99 Million TWD | -29.56% |
2023 Q2 | 606.96 Million TWD | 93.31% |
2023 Q3 | 322.87 Million TWD | -46.8% |
2022 Q1 | 431 Million TWD | -18.89% |
2022 FY | 1.77 Billion TWD | 9.25% |
2022 Q4 | 445.78 Million TWD | 1.39% |
2022 Q3 | 439.68 Million TWD | -5.11% |
2022 Q2 | 463.36 Million TWD | 7.51% |
2021 Q3 | 376.75 Million TWD | -3.85% |
2021 Q2 | 391.83 Million TWD | 19.06% |
2021 FY | 1.62 Billion TWD | 21.44% |
2021 Q1 | 329.09 Million TWD | -23.31% |
2021 Q4 | 531.4 Million TWD | 41.05% |
2020 Q3 | 296.13 Million TWD | 6.42% |
2020 Q4 | 429.09 Million TWD | 44.9% |
2020 Q1 | 337.93 Million TWD | -37.67% |
2020 Q2 | 278.25 Million TWD | -17.66% |
2020 FY | 1.34 Billion TWD | -4.55% |
2019 Q1 | 347.67 Million TWD | -28.96% |
2019 Q3 | 287.5 Million TWD | 26.12% |
2019 Q4 | 542.16 Million TWD | 88.58% |
2019 FY | 1.4 Billion TWD | -4.13% |
2019 Q2 | 227.96 Million TWD | -34.43% |
2018 Q2 | 334.74 Million TWD | 8.38% |
2018 Q4 | 489.41 Million TWD | 47.05% |
2018 FY | 1.46 Billion TWD | 6.74% |
2018 Q1 | 308.86 Million TWD | -24.45% |
2018 Q3 | 332.82 Million TWD | -0.57% |
2017 Q1 | 331.9 Million TWD | -33.49% |
2017 FY | 1.37 Billion TWD | -2.64% |
2017 Q4 | 408.82 Million TWD | 29.87% |
2017 Q3 | 314.78 Million TWD | -0.94% |
2017 Q2 | 317.77 Million TWD | -4.26% |
2016 Q1 | 279.22 Million TWD | -37.5% |
2016 FY | 1.41 Billion TWD | -7.81% |
2016 Q2 | 287.52 Million TWD | 2.97% |
2016 Q3 | 344.78 Million TWD | 19.91% |
2016 Q4 | 499.01 Million TWD | 44.73% |
2015 Q1 | 330.43 Million TWD | -23.08% |
2015 FY | 1.52 Billion TWD | 22.14% |
2015 Q4 | 446.75 Million TWD | 32.62% |
2015 Q3 | 336.88 Million TWD | -19.0% |
2015 Q2 | 415.91 Million TWD | 25.87% |
2014 Q3 | 275.55 Million TWD | 8.39% |
2014 FY | 1.25 Billion TWD | -14.14% |
2014 Q1 | 293.31 Million TWD | -28.86% |
2014 Q2 | 254.23 Million TWD | -13.32% |
2014 Q4 | 429.57 Million TWD | 55.89% |
2013 Q3 | 333.72 Million TWD | 4.8% |
2013 Q4 | 412.33 Million TWD | 23.56% |
2013 Q1 | 394.52 Million TWD | -16.42% |
2013 Q2 | 318.44 Million TWD | -19.28% |
2013 FY | 1.45 Billion TWD | 9.33% |
2012 Q4 | 472.04 Million TWD | 67.05% |
2012 FY | 1.33 Billion TWD | 3.54% |
2012 Q1 | 300.76 Million TWD | -17.85% |
2012 Q2 | 278.78 Million TWD | -7.31% |
2012 Q3 | 282.58 Million TWD | 1.37% |
2011 Q2 | 304.2 Million TWD | 4.48% |
2011 FY | 1.28 Billion TWD | 13.3% |
2011 Q4 | 366.11 Million TWD | 11.82% |
2011 Q3 | 327.41 Million TWD | 7.63% |
2011 Q1 | 291.16 Million TWD | 12.13% |
2010 FY | 1.13 Billion TWD | 7.07% |
2010 Q4 | 259.67 Million TWD | -5.57% |
2010 Q3 | 274.99 Million TWD | -26.08% |
2010 Q2 | 372.01 Million TWD | 61.08% |
2010 Q1 | 230.94 Million TWD | 0.0% |
2009 FY | 1.06 Billion TWD | 15.71% |
2008 FY | 918.19 Million TWD | 61.0% |
2007 FY | 570.29 Million TWD | -1.3% |
2006 FY | 577.81 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sinon Corporation | 5.19 Billion TWD | 74.813% |
All Cosmos Bio-Tech Holding Corporation | 375.98 Million TWD | -248.314% |
CH Biotech R&D Co., Ltd. | 694.23 Million TWD | -88.642% |